Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Receivables for 8 consecutive years, with $23.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 114.52% year-over-year to $23.3 million, compared with a TTM value of $23.3 million through Dec 2025, up 114.52%, and an annual FY2025 reading of $23.3 million, up 114.52% over the prior year.
  • Receivables was $23.3 million for Q4 2025 at Zevra Therapeutics, up from $16.8 million in the prior quarter.
  • Across five years, Receivables topped out at $23.3 million in Q4 2025 and bottomed at $1.6 million in Q4 2021.
  • Average Receivables over 5 years is $9.9 million, with a median of $9.2 million recorded in 2022.
  • Peak annual rise in Receivables hit 475.72% in 2022, while the deepest fall reached 71.64% in 2022.
  • Year by year, Receivables stood at $1.6 million in 2021, then skyrocketed by 475.72% to $9.4 million in 2022, then surged by 97.97% to $18.6 million in 2023, then tumbled by 41.82% to $10.8 million in 2024, then surged by 114.52% to $23.3 million in 2025.
  • Business Quant data shows Receivables for ZVRA at $23.3 million in Q4 2025, $16.8 million in Q3 2025, and $18.3 million in Q2 2025.